Potassium and the dyskalemias

Core Concepts in the Disorders of Fluid, Electrolytes and Acid-Base Balance

Volumn , Issue , 2013, Pages 49-102

  Segal, Alan ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84894438120     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-3770-3_3     Document Type: Chapter

References (232)

1. Fulop M. Hyperkalemia in diabetic ketoacidosis. Am J Med Sci. 1990;299:164-9.
2. Singhal PC, Venkatesan J, Gibbons N, Gibbons J. Prevalence and predictors of rhabdomyolysis in patients with hypokalemia. N Engl J Med. 1990;323:1488.
3. Helfant RH. Hypokalemia and arrhythmias. Am J Med. 1986;80:13-22.
4. Mandal AK. Hypokalemia and hyperkalemia. Med Clin North Am. 1997;81:611-39.
5. Schwartz WB, Relman AS. Effects of electrolyte disorders on renal structure and function. N Engl J Med. 1967;276:383-9. contd.
6. Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol. 2008;3:324-30.
7. Littmann L, Monroe MH, Taylor III L, Brearley Jr. WD. The hyperkalemic Brugada sign. J Electrocardiol. 2007;40:53-9.
8. Tanawuttiwat T, Harindhanavudhi T, Bhan A, Dia M. Hyperkalemia-induced Brugada pattern: An unusual manifestation. J Cardiovasc Med (Hagerstown). 2010;11:285-7.
9. Mason B. Principles of geochemistry. III ed. New York: Wiley; 1966.
10. Hardison R. Hemoglobins from bacteria to man: evolution of different patterns of gene expression. J Exp Biol. 1998;201:1099-117.
11. Clausen T. Na +-K + pump regulation and skeletal muscle contractility. Physiol Rev. 2003;83:1269-324.
12. Stein WD. The sodium pump in the evolution of animal cells. Philos Trans R Soc Lond B Biol Sci. 1995;349:263-9.
13. Hebert SC, Desir G, Giebisch G, Wang W. Molecular diversity and regulation of renal potassium channels. Physiol Rev. 2005;85:319-71.
14. Bygrave FL. The ionic environment and metabolic control. Nature. 1967;214:667-71.
15. Giebisch GH. A trail of research on potassium. Kidney Int. 2002;62:1498-512.
16. Mills B, Tupper JT. Cell cycle dependent changes in potassium transport. J Cell Physiol. 1976;89: 123-32.
17. Davy H. 1807 Bakerian Lecture: on some new phenomena of chemical changes produced by electricity, particularly the decomposition of fi xed alkalies, and the exhibition of the new substances which constitute their bases: And on the general nature of alkaline bodies. Philos Trans R Soc. 1808;98:1-44.
18. Skou JC. The in fl uence of some cations on an adenosine triphosphatase from peripheral nerves. Biochim Biophys Acta. 1957;23:394-401.
19. Gennari FJ, Segal AS. Hyperkalemia: An adaptive response in chronic renal insuf fi ciency. Kidney Int. 2002;62:1-9.
20. Dluhy RG, Axelrod L, Williams GH. Serum immunoreactive insulin and growth hormone response to potassium infusion in normal man. J Appl Physiol. 1972;33:22-6.
21. Rosa RM, Silva P, Young JB, et al. Adrenergic modulation of extrarenal potassium disposal. N Engl J Med. 1980;302:431-4.
22. Brown RS. Extrarenal potassium homeostasis. Kidney Int. 1986;30:116-27.
23. Bia MJ, Lu D, Tyler K, De Fronzo RA. Beta adrenergic control of extrarenal potassium disposal. A beta-2 mediated phenomenon. Nephron. 1986;43:117-22.
24. Akaike N. Sodium pump in skeletal muscle: central nervous system-induced suppression by alphaadrenoreceptors. Science (New York, NY). 1981;213:1252-4.
25. Williams ME, Rosa RM, Silva P, Brown RS, Epstein FH. Impairment of extrarenal potassium disposal by alpha-adrenergic stimulation. N Engl J Med. 1984;311:145-9.
26. Clausen T. Hormonal and pharmacological modi fi cation of plasma potassium homeostasis. Fundam Clin Pharmacol. 2010;24:595-605.
27. Rigato I, Blarasin L, Kette F. Severe hypokalemia in 2 young bicycle riders due to massive caffeine intake. Clin J Sport Med. 2010;20:128-30.
28. Passmore AP, Kondowe GB, Johnston GD. Caffeine and hypokalemia. Ann Intern Med. 1986;105:468.
29. Mudge DW, Johnson DW. Coca-Cola and kangaroos. Lancet. 2004;364:1190.
30. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51:83-133.
31. Moreno M, Murphy C, Goldsmith C. Increase in serum potassium resulting from the administration of hypertonic mannitol and other solutions. J Lab Clin Med. 1969;73:291-8.
32. Sirken G, Raja R, Garces J, Bloom E, Fumo P. Contrast-induced translocational hyponatremia and hyperkalemia in advanced kidney disease. Am J Kidney Dis. 2004;43:e31-5.
33. Goldfarb S, Cox M, Singer I, Goldberg M. Acute hyperkalemia induced by hyperglycemia: hormonal mechanisms. Ann Intern Med. 1976;84:426-32.
34. Viberti GC. Glucose-induced hyperkalaemia: A hazard for diabetics? Lancet. 1978;1:690-1.
35. Conte G, Dal Canton A, Imperatore P, et al. Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure. Kidney Int. 1990;38:301-7.
36. Adrogue HJ, Madias NE. PCO 2 and [K+]p in metabolic acidosis: certainty for the fi rst and uncertainty for the other. J Am Soc Nephrol. 2004;15:1667-8.
37. Adrogue HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med. 1981;71:456-67.
38. Krapf R, Caduff P, Wagdi P, Staubli M, Hulter HN. Plasma potassium response to acute respiratory alkalosis. Kidney Int. 1995;47:217-24.
39. Jones JW, Sebastian A, Hulter HN, Schambelan M, Sutton JM, Biglieri EG. Systemic and renal acidbase effects of chronic dietary potassium depletion in humans. Kidney Int. 1982;21:402-10.
40. Rector Jr. FC, Bloomer HA, Seldin DW. Effect of potassium de fi ciency on the reabsorption of bicarbonate in the proximal tubule of the rat kidney. J Clin Invest. 1964;43:1976-82.
41. Soleimani M, Burnham CE. Physiologic and molecular aspects of the Na + :HCO 3 cotransporter in health and disease processes. Kidney Int. 2000;57: 371-84.
42. Fulop M. Serum potassium in lactic acidosis and ketoacidosis. N Engl J Med. 1979;300:1087-9.
43. Wiederseiner JM, Muser J, Lutz T, Hulter HN, Krapf R. Acute metabolic acidosis: characterization and diagnosis of the disorder and the plasma potassium response. J Am Soc Nephrol. 2004;15:1589-96.
44. Berliner RW, Kennedy Jr. TJ, Hilton JG. Renal mechanisms for excretion of potassium. Am J Physiol. 1950;162:348-67.
45. Giebisch G, Stanton B. Potassium transport in the nephron. Annu Rev Physiol. 1979;41:241-56.
46. O'Neil RG, Hayhurst RA. Functional differentiation of cell types of cortical collecting duct. Am J Physiol. 1985;248:F449-53.
47. Madsen KM, Tisher CC. Structural-functional relationships along the distal nephron. Am J Physiol. 1986;250:F1-15.
48. Woda CB, Leite Jr. M, Rohatgi R, Satlin LM. Effects of luminal fl ow and nucleotides on [Ca 2+ ]i in rabbit cortical collecting duct. Am J Physiol Renal Physiol. 2002;283:F437-46.
49. Palmer LG, Frindt G. High-conductance K channels in intercalated cells of the rat distal nephron. Am J Physiol Renal Physiol. 2007;292:F966-73.
50. Holtzclaw JD, Grimm PR, Sansom SC. Intercalated cell BK-alpha/beta4 channels modulate sodium and potassium handling during potassium adaptation. J Am Soc Nephrol. 2010;21:634-45.
51. Grimm PR, Irsik DL, Liu L, Holtzclaw JD, Sansom SC. Role of BKbeta1 in Na + reabsorption by cortical collecting ducts of Na +-deprived mice. Am J Physiol Renal Physiol. 2009;297:F420-8.
52. Giebisch G, Krapf R, Wagner C. Renal and extrarenal regulation of potassium. Kidney Int. 2007;72: 397-410.
53. DuBose Jr. TD, Gitomer J, Codina J. H +, K +-ATPase. Curr Opin Nephrol Hypertens. 1999;8:597-602.
54. Field MJ, Stanton BA, Giebisch GH. Differential acute effects of aldosterone, dexamethasone, and hyperkalemia on distal tubular potassium secretion in the rat kidney. J Clin Invest. 1984;74: 1792-802.
55. Muto S. Potassium transport in the mammalian collecting duct. Physiol Rev. 2001;81:85-116.
56. Alvarez de la Rosa D, Gimenez I, Forbush B, Canessa CM. SGK1 activates Na +-K +-ATPase in amphibian renal epithelial cells. Am J Physiol Cell Physiol. 2006;290:C492-8.
57. Alvarez de la Rosa D, Zhang P, Naray-Fejes-Toth A, Fejes-Toth G, Canessa CM. The serum and gluco corticoid kinase sgk increases the abundance of epithelial sodium channels in the plasma membrane of Xenopus oocytes. J Biol Chem. 1999;274:37834-9.
58. Pearce D, Kleyman TR. Salt, sodium channels, and SGK1. J Clin Invest. 2007;117:592-5.
59. Ring AM, Leng Q, Rinehart J, et al. An SGK1 site in WNK4 regulates Na + channel and K + channel activity and has implications for aldosterone signaling and K + homeostasis. Proc Natl Acad Sci U S A. 2007;104:4025-9.
60. Shimkets RA, Warnock DG, Bositis CM, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell. 1994;79:407-14.
61. Wilson FH, Disse-Nicodeme S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science (New York, NY). 2001;293:1107-12.
62. Kahle KT, Wilson FH, Leng Q, et al. WNK4 regulates the balance between renal NaCl reabsorption and K + secretion. Nat Genet. 2003;35:372-6.
63. Ring AM, Cheng SX, Leng Q, et al. WNK4 regulates activity of the epithelial Na + channel in vitro and in vivo. Proc Natl Acad Sci U S A. 2007;104: 4020-4.
64. Rastegar A, Biemesderfer D, Kashgarian M, Hayslett JP. Changes in membrane surfaces of collecting duct cells in potassium adaptation. Kidney Int. 1980;18:293-301.
65. Good DW, Wright FS. Luminal in fl uences on potassium secretion: sodium concentration and fl uid fl ow rate. Am J Physiol. 1979;236:F192-205.
66. Good DW, Velazquez H, Wright FS. Luminal in fl uences on potassium secretion: low sodium concentration. Am J Physiol. 1984;246:F609-19.
67. Woda CB, Bragin A, Kleyman TR, Satlin LM. Flowdependent K + secretion in the cortical collecting duct is mediated by a maxi-K channel. Am J Physiol Renal Physiol. 2001;280:F786-93.
68. Taniguchi J, Imai M. Flow-dependent activation of maxi K + channels in apical membrane of rabbit connecting tubule. J Membr Biol. 1998;164:35-45.
69. Satlin LM, Sheng S, Woda CB, Kleyman TR. Epithelial Na + channels are regulated by fl ow. Am J Physiol Renal Physiol. 2001;280:F1010-8.
70. Gennari FJ, Goldstein MB, Schwartz WB. The nature of the renal adaptation to chronic hypocapnia. J Clin Invest. 1972;51:1722-30.
71. Kassirer JP, Schwartz WB. The response of normal man to selective depletion of hydrochloric acid. Factors in the genesis of persistent gastric alkalosis. Am J Med. 1966;40:10-8.
72. Klastersky J, Vanderklen B, Daneau D, Mathiew M. Carbenicillin and hypokalemia. Ann Intern Med. 1973;78:774-5.
73. Ellison DH, Velazquez H, Wright FS. Stimulation of distal potassium secretion by low lumen chloride in the presence of barium. Am J Physiol. 1985;248: F638-49.
74. Amorim JB, Bailey MA, Musa-Aziz R, Giebisch G, Malnic G. Role of luminal anion and pH in distal tubule potassium secretion. Am J Physiol Renal Physiol. 2003;284:F381-8.
75. Welt LG. Experimental magnesium depletion. Yale J Biol Med. 1964;36:325-49.
76. Whang R, Welt LG. Observations in experimental magnesium depletion. J Clin Invest. 1963;42:305-13.
77. Altura BM, Altura BT. Interactions of Mg and K on blood vessels-aspects in view of hypertension. Review of present status and new fi ndings. Magnesium. 1984;3:175-94.
78. Matsuda H, Saigusa A, Irisawa H. Ohmic conductance through the inwardly rectifying K channel and blocking by internal Mg 2+ . Nature. 1987;325:156-9.
79. Lu Z, MacKinnon R. Electrostatic tuning of Mg 2+ af fi nity in an inward-recti fi er K + channel. Nature. 1994;371:243-6.
80. Yang L, Frindt G, Palmer LG. Magnesium modulates ROMK channel-mediated potassium secretion. J Am Soc Nephrol. 2010;21:2109-16.
81. Huang CL, Kuo E. Mechanism of hypokalemia in magnesium de fi ciency. J Am Soc Nephrol. 2007;18:2649-52.
82. Wei Y, Zavilowitz B, Satlin LM, Wang WH. Angiotensin II inhibits the ROMK-like small conductance K channel in renal cortical collecting duct during dietary potassium restriction. J Biol Chem. 2007;282:6455-62.
83. Yue P, Sun P, Lin DH, Pan C, Xing W, Wang W. Angiotensin II diminishes the effect of SGK1 on the WNK4-mediated inhibition of ROMK1 channels. Kidney Int. 2011;79:423-31.
84. Schnermann J, Homer W. Smith Award lecture. The juxtaglomerular apparatus: from anatomical peculiarity to physiological relevance. J Am Soc Nephrol. 2003;14:1681-94.
85. Adrogue HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med. 2007;356:1966-78.
86. Rimmer JM, Horn JF, Gennari FJ. Hyperkalemia as a complication of drug therapy. Arch Intern Med. 1987;147:867-9.
87. Satlin LM, Carattino MD, Liu W, Kleyman TR. Regulation of cation transport in the distal nephron by mechanical forces. Am J Physiol Renal Physiol. 2006;291:F923-31.
88. Field MJ, Stanton BA, Giebisch GH. Influence of ADH on renal potassium handling: A micropuncture and microperfusion study. Kidney Int. 1984;25:502-11.
89. Greenberg A. Diuretic complications. Am J Med Sci. 2000;319:10-24.
90. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med. 2000;109:307-14.
91. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709-17.
92. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351:543-51.
93. Loughlin J, Seeger JD, Eng PM, et al. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. Contraception. 2008;78:377-83.
94. Genazzani AR, Mannella P, Simoncini T. Drospirenone and its antialdosterone properties. Climacteric. 2007;10 Suppl 1:11-8.
95. Hajjar IM, Grim CE, George V, Kotchen TA. Impact of diet on blood pressure and age-related changes in blood pressure in the US population: Analysis of NHANES III. Arch Intern Med. 2001;161:589-93.
96. Institute of Medicine. Dietary reference intakes for water, potassium, sodium, chloride, and sulfate. In: Food and Nutrition Board. Washington, DC: National Academies Press; 2004. p. 173-246.
97. Rabinowitz L, Green DM, Sarason RL, Yamauchi H. Homeostatic potassium excretion in fed and fasted sheep. Am J Physiol. 1988;254:R357-80.
98. Lee FN, Oh G, McDonough AA, Youn JH. Evidence for gut factor in K + homeostasis. Am J Physiol Renal Physiol. 2007;293:F541-7.
99. Greenfeld D, Mickley D, Quinlan DM, Roloff P. Hypokalemia in outpatients with eating disorders. Am J Psychiatry. 1995;152:60-3.
100. Elisaf M, Liberopoulos E, Bairaktari E, Siamopoulos K. Hypokalaemia in alcoholic patients. Drug Alcohol Rev. 2002;21:73-6.
101. Gennari FJ. Hypokalemia. N Engl J Med. 1998;339:451-8.
102. Lin SH. Thyrotoxic periodic paralysis. Mayo Clin Proc. 2005;80:99-105.
103. Cannon SC. Pathomechanisms in channelopathies of skeletal muscle and brain. Annu Rev Neurosci. 2006;29:387-415.
104. Jurkat-Rott K, Mitrovic N, Hang C, et al. Voltagesensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current. Proc Natl Acad Sci U S A. 2000;97:9549-54.
105. Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Arch Intern Med. 1999;159:601-6.
106. Ryan DP, da Silva MR, Soong TW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell. 2010;140:88-98.
107. Lin SH, Lin YF, Chen DT, Chu P, Hsu CW, Halperin ML. Laboratory tests to determine the cause of hypokalemia and paralysis. Arch Intern Med. 2004;164:1561-6.
108. Lin SH, Chu P, Cheng CJ, Chu SJ, Hung YJ, Lin YF. Early diagnosis of thyrotoxic periodic paralysis: spot urine calcium to phosphate ratio. Crit Care Med. 2006;34:2984-9.
109. Ko GT, Chow CC, Yeung VT, Chan HH, Li JK, Cockram CS. Thyrotoxic periodic paralysis in a Chinese population. QJM. 1996;89:463-8.
110. Lin SH, Lin YF. Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis. Am J Kidney Dis. 2001;37:620-3.
111. Huang TY, Lin SH. Thyrotoxic hypokalemic periodic paralysis reversed by propranolol without rebound hyperkalemia. Ann Emerg Med. 2001;37: 415-6.
112. Brambilla G, Cenci T, Franconi F, et al. Clinical and pharmacological pro fi le in a clenbuterol epidemic poisoning of contaminated beef meat in Italy. Toxicol Lett. 2000;114:47-53.
113. Bahlmann H, Lindwall R, Persson H. Acute barium nitrate intoxication treated by hemodialysis. Acta Anaesthesiol Scand. 2005;49:110-2.
114. Brown RS. Potassium homeostasis and clinical implications. Am J Med. 1984;77:3-10.
115. Knochel JP, Dotin LN, Hamburger RJ. Pathophysiology of intense physical conditioning in a hot climate. I. Mechanisms of potassium depletion. J Clin Invest. 1972;51:242-55.
116. Schwartz WB, Kassirer JP. Medical management of chronic renal failure. Am J Med. 1968;44:786-802.
117. Solomon R. The relationship between disorders of K + and Mg 2+ homeostasis. Semin Nephrol. 1987;7: 253-62.
118. Gill Jr. JR, Frolich JC, Bowden RE, et al. Bartter's syndrome: A disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis. Am J Med. 1976;61:43-51.
119. Stein JH. The pathogenetic spectrum of Bartter's syndrome. Kidney Int. 1985;28:85-93.
120. Simon DB, Lifton RP. The molecular basis of inherited hypokalemic alkalosis: Bartter's and Gitelman's syndromes. Am J Physiol. 1996;271:F961-6.
121. Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet. 1996;13:183-8.
122. Rodriguez-Soriano J. Bartter and related syndromes: The puzzle is almost solved. Pediatr Nephrol (Berlin, Germany). 1998;12:315-27.
123. Wrong O, Metcalfe-Gibson A, Morrison RB, Ng ST, Howard AV. In vivo dialysis of faeces as a method of stool analysis. I. Technique and results in normal subjects. Clin Sci. 1965;28:357-75.
124. Kavic SM, Frehm EJ, Segal AS. Case studies in cholera: lessons in medical history and science. Yale J Biol Med. 1999;72:393-408.
125. Oster JR, Materson BJ, Rogers AI. Laxative abuse syndrome. Am J Gastroenterol. 1980;74:451-8.
126. de Wolff FA, de Haas EJ, Verweij M. A screening method for establishing laxative abuse. Clin Chem. 1981;27:914-7.
127. Shelton JH, Santa Ana CA, Thompson DR, Emmett M, Fordtran JS. Factitious diarrhea induced by stimulant laxatives: Accuracy of diagnosis by a clinical reference laboratory using thin layer chromatography. Clin Chem. 2007;53:85-90.
128. Holmberg C. Congenital chloride diarrhoea. Clin Gastroenterol. 1986;15:583-602.
129. Blondon H, Bechade D, Desrame J, Algayres JP. Secretory diarrhoea with high faecal potassium concentrations: A new mechanism of diarrhoea associated with colonic pseudo-obstruction? Report of fi ve patients. Gastroenterol Clin Biol. 2008;32:401-4.
130. Simon M, Duong JP, Mallet V, et al. Over-expression of colonic K + channels associated with severe potassium secretory diarrhoea after haemorrhagic shock. Nephrol Dial Transplant. 2008;23:3350-2.
131. Van Dinter Jr. TG, Fuerst FC, Richardson CT, et al. Stimulated active potassium secretion in a patient with colonic pseudo-obstruction: A new mechanism of secretory diarrhea. Gastroenterology. 2005;129: 1268-73.
132. Sandle GI, Hunter M. Apical potassium (BK) channels and enhanced potassium secretion in human colon. QJM. 2010;103:85-9.
133. Sebastian A, McSherry E, Morris Jr. RC. On the mechanism of renal potassium wasting in renal tubular acidosis associated with the Fanconi syndrome (type 2 RTA). J Clin Invest. 1971;50:231-43.
134. Messiaen T, Deret S, Mougenot B, et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine. 2000;79:135-54.
135. Estevez R, Boettger T, Stein V, et al. Barttin is a Cl channel beta-subunit crucial for renal Cl reabsorption and inner ear K + secretion. Nature. 2001;414: 558-61.
136. Miyamura N, Matsumoto K, Taguchi T, et al. Atypical Bartter syndrome with sensorineural deafness with G47R mutation of the beta-subunit for ClC-Ka and ClC-Kb chloride channels, barttin. J Clin Endocrinol Metabol. 2003;88:781-6.
137. Schlingmann KP, Konrad M, Jeck N, et al. Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med. 2004;350:1314-9.
138. Vargas-Poussou R, Huang C, Hulin P, et al. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol. 2002;13:2259-66.
139. Cruz DN, Shaer AJ, Bia MJ, Lifton RP, Simon DB. Gitelman's syndrome revisited: An evaluation of symptoms and health-related quality of life. Kidney Int. 2001;59:710-7.
140. Batlle D, Moorthi KM, Schlueter W, Kurtzman N. Distal renal tubular acidosis and the potassium enigma. Semin Nephrol. 2006;26:471-8.
141. Sebastian A, McSherry E, Morris Jr. RC. Impaired renal conservation of sodium and chloride during sustained correction of systemic acidosis in patients with type 1, classic renal tubular acidosis. J Clin Invest. 1976;58:454-69.
142. Taher SM, Anderson RJ, McCartney R, Popovtzer MM, Schrier RW. Renal tubular acidosis associated with toluene "snif fi ng". N Engl J Med. 1974;290: 765-8.
143. Streicher HZ, Gabow PA, Moss AH, Kono D, Kaehny WD. Syndromes of toluene snif fi ng in adults. Ann Intern Med. 1981;94:758-62.
144. Carlisle EJ, Donnelly SM, Vasuvattakul S, Kamel KS, Tobe S, Halperin ML. Glue-snif fi ng and distal renal tubular acidosis: sticking to the facts. J Am Soc Nephrol. 1991;1:1019-27.
145. Gill Jr. JR, George JM, Solomon A, Bartter FC. Hyperaldosteronism and renal sodium loss reversed by drug treatment for malignant hypertension. N Engl J Med. 1964;270:1088-92.
146. Lenz T, Thiede HM, Nussberger J, Atlas SA, Distler A, Schulte KL. Hyperreninemia and secondary hyperaldosteronism in a patient with pheochromocytoma and von Hippel-Lindau disease. Nephron. 1992;62:345-50.
147. Leogite J, Schillo F, Viennet G, et al. Reninoma: A rare but curable cause of high blood pressure, a case report. Ann Endocrinol. 2003;64:198-201.
148. Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism. A detectable cause of curable "essential" hypertension. JAMA. 1965;193:200-6.
149. Schirpenbach C, Reincke M. Primary aldosteronism: current knowledge and controversies in Conn's syndrome. Nat Clin Pract. 2007;3:220-7.
150. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg. 1964;107:159-72.
151. Marples D, Frokiaer J, Dorup J, Knepper MA, Nielsen S. Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest. 1996;97: 1960-8.
152. Choi M, Scholl UI, Yue P, et al. K + channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331: 768-72.
153. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262-5.
154. Orth DN. Cushing's syndrome. N Engl J Med. 1995;332:791-803.
155. Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: A series of 58 cases. Ann N Y Acad Sci. 2002;970: 134-44.
156. Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science (New York, NY). 2000;289:119-23.
157. Morineau G, Sulmont V, Salomon R, et al. Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. J Am Soc Nephrol. 2006;17:3176-84.
158. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet. 1995;10:394-9.
159. van Uum SH. Liquorice and hypertension. Neth J Med. 2005;63:119-20.
160. Mumoli N, Cei M. Licorice-induced hypokalemia. Int J Cardiol. 2008;124:e42-4.
161. Serra A, Uehlinger DE, Ferrari P, et al. Glycyrrhetinic acid decreases plasma potassium concentrations in patients with anuria. J Am Soc Nephrol. 2002;13:191-6.
162. Rossier BC. 1996 Homer Smith Award Lecture. Cum grano salis: The epithelial sodium channel and the control of blood pressure. J Am Soc Nephrol. 1997;8:980-92.
163. Snyder PM. Minireview: regulation of epithelial Na + channel traf fi cking. Endocrinology. 2005;146:5079-85.
164. Liddle GW, Bledsoe T, Coppage WS. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians. 1963;76:99-213.
165. Gennari FJ, Hussain-Khan S, Segal A. An unusual case of metabolic alkalosis: A window into the pathophysiology and diagnosis of this common acidbase disturbance. Am J Kidney Dis. 2010;55:1130-5.
166. Sterns RH, Cox M, Feig PU, Singer I. Internal potassium balance and the control of the plasma potassium concentration. Medicine. 1981;60:339-54.
167. Murakami K, Tomita M, Kawamura N, et al. Severe metabolic acidosis and hypokalemia in a patient with enterovesical fi stula. Clin Exp Nephrol. 2007;11: 225-9.
168. Murthy K, Harrington JT, Siegel RD. Profound hypokalemia in diabetic ketoacidosis: A therapeutic challenge. Endocr Pract. 2005;11:331-4.
169. Yasue H, Itoh T, Mizuno Y, Harada E. Severe hypokalemia, rhabdomyolysis, muscle paralysis, and respiratory impairment in a hypertensive patient taking herbal medicines containing licorice. Intern Med. 2007;46:575-8.
170. Kunin AS, Surawicz B, Sims EA. Decrease in serum potassium concentrations and appearance of cardiac arrhythmias during infusion of potassium with glucose in potassium-depleted patients. N Engl J Med. 1962;266:228-33.
171. Kruse JA, Carlson RW. Rapid correction of hypokalemia using concentrated intravenous potassium chloride infusions. Arch Intern Med. 1990;150: 613-7.
172. Hamill RJ, Robinson LM, Wexler HR, Moote C. Ef fi cacy and safety of potassium infusion therapy in hypokalemic critically ill patients. Crit Care Med. 1991;19:694-9.
173. Sugimoto T, Kume S, Osawa N, Nakazawa J, Koya D, Kashiwagi A. Familial pseudohyperkalemia: A rare cause of hyperkalemia. Intern Med. 2005;44: 875-8.
174. Bywaters EGL, Beall D. Crush injuries with impairment of renal function. Br Med J. 1941;1:427.
175. Grossman RA, Hamilton RW, Morse BM, Penn AS, Goldberg M. Nontraumatic rhabdomyolysis and acute renal failure. N Engl J Med. 1974;291:807-11.
176. Gowda RM, Cohen RA, Khan IA. Toad venom poisoning: resemblance to digoxin toxicity and therapeutic implications. Heart (British Cardiac Society). 2003;89:e14.
177. Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology. 2006;104:158-69.
178. Lehmann-Horn F, Jurkat-Rott K. Voltage-gated ion channels and hereditary disease. Physiol Rev. 1999;79:1317-72.
179. Ptacek LJ, Johnson KJ, Griggs RC. Genetics and physiology of the myotonic muscle disorders. N Engl J Med. 1993;328:482-9.
180. Pickar JG, Spier SJ, Snyder JR, Carlsen RC. Altered ionic permeability in skeletal muscle from horses with hyperkalemic periodic paralysis. Am J Physiol. 1991;260:C926-33.
181. Cruz DN, Perazella MA. Biochemical aberrations in a dialysis patient following parathyroidectomy. Am J Kidney Dis. 1997;29:759-62.
182. Armstrong CM. Distinguishing surface effects of calcium ion from pore-occupancy effects in Na + channels. Proc Natl Acad Sci U S A. 1999;96: 4158-63.
183. Ponce SP, Jennings AE, Madias NE, Harrington JT. Drug-induced hyperkalemia. Medicine. 1985;64:357-70.
184. Perry MC. Cautopyreiophagia. N Engl J Med. 1977;296:824.
185. Abu-Hamdan DK, Sondheimer JH, Mahajan SK. Cautopyreiophagia. Cause of life-threatening hyperkalemia in a patient undergoing hemodialysis. Am J Med. 1985;79:517-9.
186. Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 1995;98:575-86.
187. Conn JW, Rovner DR, Cohen EL, Anderson Jr. JE. Inhibition by heparinoid of aldosterone biosynthesis in man. J Clin Endocrinol Metabol. 1966;26: 527-32.
188. Wilson ID, Goetz FC. Selective hypoaldosteronism after prolonged heparin administration. A case report, with postmortem fi ndings. Am J Med. 1964;36:635-40.
189. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351:585-92.
190. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75: 793-5.
191. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998;158:26-32.
192. Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 2000;58:2084-92.
193. Preston RA, Baltodano NM, Alonso AB, Epstein M. Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus. J Clin Pharmacol. 2002;42:754-61.
194. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ (Clinical research ed). 2003;327:1141-2.
195. Velazquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119: 296-301.
196. Szerlip HM, Weiss J, Singer I. Profound hyperkalemia without electrocardiographic manifestations. Am J Kidney Dis. 1986;7:461-5.
197. Keith NM, Osterberg AE, Burchell HB. Some effects of potassium salts in man. Ann Intern Med. 1942;16:879-92.
198. Thomson WAR. The effect of potassium on the heart in man. Br Heart J. 1939;1:269-82.
199. Tarail R. Relationship of abnormalities in concentration of serum potassium to electrocardiographic disturbances. Am J Med. 1948;5:828-37.
200. Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol Rev. 2005;85:1205-53.
201. Frankenhaeuser B, Hodgkin AL. The action of calcium on the electrical properties of squid axons. J Physiol. 1957;137:218-44.
202. Armstrong CM, Cota G. Calcium ion as a cofactor in Na channel gating. Proc Natl Acad Sci U S A. 1991;88:6528-31.
203. Armstrong CM, Cota G. Calcium block of Na + channels and its effect on closing rate. Proc Natl Acad Sci U S A. 1999;96:4154-7.
204. Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. J Am Soc Nephrol. 1995;6:1134-42.
205. Gold H, Kwit N. Digitalis and calcium synergism. Science (New York, NY). 1937;86:330-1.
206. Smith PK, Winkler AW, Hoff HE. Calcium and digitalis synergism: The toxicity of calcium salts injected intravenously into digitalized animals. Arch Int Med. 1939;64:322-8.
207. Lown B, Black H, Moore FD. Digitalis, electrolytes and the surgical patient. Am J Cardiol. 1960;6:309-37.
208. Nola GT, Pope S, Harrison DC. Assessment of the synergistic relationship between serum calcium and digitalis. Am Heart J. 1970;79:499-507.
209. Fenton F, Smally AJ, Laut J. Hyperkalemia and digoxin toxicity in a patient with kidney failure. Ann Emerg Med. 1996;28:440-1.
210. Van Deusen SK, Birkhahn RH, Gaeta TJ. Treatment of hyperkalemia in a patient with unrecognized digitalis toxicity. J Toxicol. 2003;41:373-6.
211. Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Ann Intern Med. 1989;110:426-9.
212. Blumberg A, Weidmann P, Shaw S, Gnadinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med. 1988;85:507-12.
213. Blumberg A, Weidmann P, Ferrari P. Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. Kidney Int. 1992;41:369-74.
214. Flatman JA, Clausen T. Combined effects of adrenaline and insulin on active electrogenic Na +-K + transport in rat soleus muscle. Nature. 1979;281: 580-1.
215. Lillemoe KD, Romolo JL, Hamilton SR, Pennington LR, Burdick JF, Williams GM. Intestinal necrosis due to sodium polystyrene (kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. Surgery. 1987;101:267-72.
216. Gerstman BB, Kirkman R, Platt R. Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. Am J Kidney Dis. 1992;20:159-61.
217. Rogers FB, Li SC. Acute colonic necrosis associated with sodium polystyrene sulfonate (Kayexalate) enemas in a critically ill patient: case report and review of the literature. J Trauma. 2001;51:395-7.
218. Kelsey PB, Chen S, Lauwers GY. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-2003. A 79-year-old man with coronary artery disease, peripheral vascular disease, end-stage renal disease, and abdominal pain and distention. N Engl J Med. 2003;349: 2147-55.
219. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ionexchange resins for the treatment of hyperkalemia: Are they safe and effective? J Am Soc Nephrol. 2010;21:733-5.
220. Watson M, Abbott KC, Yuan CM. Damned if you do, damned if you don't: potassium binding resins in hyperkalemia. Clin J Am Soc Nephrol. 2010;5:1723-6.
221. McGowan CE, Saha S, Chu G, Resnick MB, Moss SF. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J. 2009;102:493-7.
222. Rashid A, Hamilton SR. Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: An underrecognized condition. Am J Surg Pathol. 1997;21:60-9.
223. Cheng ES, Stringer KM, Pegg SP. Colonic necrosis and perforation following oral sodium polystyrene sulfonate (Resonium A/Kayexalate) in a burn patient. Burns. 2002;28:189-90.
224. Emmett M, Hootkins RE, Fine KD, Santa Ana CA, Porter JL, Fordtran JS. Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion. Gastroenterology. 1995;108: 752-60.
225. Dardik A, Moesinger RC, Efron G, Barbul A, Harrison MG. Acute abdomen with colonic necrosis induced by Kayexalate-sorbitol. South Med J. 2000;93:511-3.
226. Gruy-Kapral C, Emmett M, Santa Ana CA, Porter JL, Fordtran JS, Fine KD. Effect of single dose resincathartic therapy on serum potassium concentration in patients with end-stage renal disease. J Am Soc Nephrol. 1998;9:1924-30.
227. Kamel KS, Wei C. Controversial issues in the treatment of hyperkalaemia. Nephrol Dial Transplant. 2003;18:2215-8.
228. Farese S, Kruse A, Pasch A, et al. Glycyrrhetinic acid food supplementation lowers serum potassium concentration in chronic hemodialysis patients. Kidney Int. 2009;76:877-84.
229. Sherman RA, Hwang ER, Bernholc AS, Eisinger RP. Variability in potassium removal by hemodialysis. Am J Nephrol. 1986;6:284-8.
230. Hou S, McElroy PA, Nootens J, Beach M. Safety and ef fi cacy of low-potassium diasylate. Am J Kidney Dis. 1989;13:137-43.
231. Karnik JA, Young BS, Lew NL, et al. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001;60:350-7.
232. Lameire N, Van Biesen W, Vanholder R. Did 20 years of technological innovations in hemodialysis contribute to better patient outcomes? Clin J Am Soc Nephrol. 2009;4 Suppl 1:S30-40.